PRESS RELEASE: NanoLogix to Exhibit at BioOhio
Post# of 9144
Posted On: 07/08/2014 1:16:05 PM
PRESS RELEASE:
NanoLogix to Exhibit at BioOhio Exposition, Receives European Allowance for BNP Patent
Supplies Product to NASA, Working with U.S. Representative Tim Ryan on Potential for Federal Contracts
HUBBARD, Ohio--(BUSINESS WIRE)--July 08, 2014--
NanoLogix, Inc. (OTCBB:NNLX), an innovator in the rapid detection of viable bacteria, and identification and determination of antibiotic resistance/sensitivity of those bacteria, announces that it is exhibiting at the BioOhio BioScience Expo and Showcase to be held in Aurora, Ohio on August 5th at the Bertram Conference Center. Sebastian Faro MD., PhD, a highly recognized authority on infectious diseases of female reproductive systems, will be presenting on the NanoLogix N-Assay Multiwell Microplate Assay during the event. NanoLogix is also a sponsor of the Expo. There is no charge for admission. Further information is available by following this link:
Patented FlatPack packaging for Petri products, exclusively licensed to NanoLogix Incorporated (Photo: Business Wire)
http://www.bioohio.com/events/expo/
European Patent
The European Patent Office has informed our London and US Patent Law firms that our European application for the NanoLogix BNP sandwiched-membrane Petri based detection technology has received an allowance for grant under the European Patent Convention. The patent will cover up to 38 member countries, dependent upon NanoLogix's election, and significantly enhances the NanoLogix Patent Portfolio. The BNP technology received patent grants in 2013 in both Japan and Russia and is currently patent pending in the United States.
NASA
At the American Society for Microbiology (ASM) annual meeting in late May, NanoLogix's display booth was visited by NASA. Upon viewing the NanoLogix Petri plates vacuum packed in nitrogen-charged FlatPacks, the following comment was made by a NASA scientist: "This is exactly what we've been looking for. We're sending these up there," referring to the International Space Station (ISS).
In early June, at NASA's request, NanoLogix supplied NASA with a number of Petri and BNP FlatPacks for their use. The company is currently awaiting further information from NASA and will release additional news as appropriate. The qualities that are of interest to NASA are the robust nature of the Petri dishes packaged in the patented FlatPack with enhanced durability and resistance to breakage, coupled with the long term room-temperature shelf life of at least two years, compared to the competition's shelf life of 3-1/2 months refrigerated.
Congressional Assistance
NanoLogix is pleased to announce that it is receiving assistance from Tim Ryan, U.S. Representative for Ohio's 13(th) Congressional District and his staff in exploring potential Federal government uses for its technologies. NanoLogix management will be traveling to Washington DC in July for meetings with the Congressman and his staff.
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical, National Defense, and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing.
Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity.
For more information visit: http://www.nanologix.com.
This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/2...006058/en/
CONTACT: NanoLogix, Inc.
Carol Surrena, 330-534-0800
info@nanologix.com
NanoLogix to Exhibit at BioOhio Exposition, Receives European Allowance for BNP Patent
Supplies Product to NASA, Working with U.S. Representative Tim Ryan on Potential for Federal Contracts
HUBBARD, Ohio--(BUSINESS WIRE)--July 08, 2014--
NanoLogix, Inc. (OTCBB:NNLX), an innovator in the rapid detection of viable bacteria, and identification and determination of antibiotic resistance/sensitivity of those bacteria, announces that it is exhibiting at the BioOhio BioScience Expo and Showcase to be held in Aurora, Ohio on August 5th at the Bertram Conference Center. Sebastian Faro MD., PhD, a highly recognized authority on infectious diseases of female reproductive systems, will be presenting on the NanoLogix N-Assay Multiwell Microplate Assay during the event. NanoLogix is also a sponsor of the Expo. There is no charge for admission. Further information is available by following this link:
Patented FlatPack packaging for Petri products, exclusively licensed to NanoLogix Incorporated (Photo: Business Wire)
http://www.bioohio.com/events/expo/
European Patent
The European Patent Office has informed our London and US Patent Law firms that our European application for the NanoLogix BNP sandwiched-membrane Petri based detection technology has received an allowance for grant under the European Patent Convention. The patent will cover up to 38 member countries, dependent upon NanoLogix's election, and significantly enhances the NanoLogix Patent Portfolio. The BNP technology received patent grants in 2013 in both Japan and Russia and is currently patent pending in the United States.
NASA
At the American Society for Microbiology (ASM) annual meeting in late May, NanoLogix's display booth was visited by NASA. Upon viewing the NanoLogix Petri plates vacuum packed in nitrogen-charged FlatPacks, the following comment was made by a NASA scientist: "This is exactly what we've been looking for. We're sending these up there," referring to the International Space Station (ISS).
In early June, at NASA's request, NanoLogix supplied NASA with a number of Petri and BNP FlatPacks for their use. The company is currently awaiting further information from NASA and will release additional news as appropriate. The qualities that are of interest to NASA are the robust nature of the Petri dishes packaged in the patented FlatPack with enhanced durability and resistance to breakage, coupled with the long term room-temperature shelf life of at least two years, compared to the competition's shelf life of 3-1/2 months refrigerated.
Congressional Assistance
NanoLogix is pleased to announce that it is receiving assistance from Tim Ryan, U.S. Representative for Ohio's 13(th) Congressional District and his staff in exploring potential Federal government uses for its technologies. NanoLogix management will be traveling to Washington DC in July for meetings with the Congressman and his staff.
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical, National Defense, and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing.
Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity.
For more information visit: http://www.nanologix.com.
This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/2...006058/en/
CONTACT: NanoLogix, Inc.
Carol Surrena, 330-534-0800
info@nanologix.com
(0)
(0)